Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Peking University First Hospital, Beijing, Beijing Municipality

The Third Medical Center of PLA General Hospital, Beijing, Beijing Municipality

Beijing Cancer Hospital, Beijing, Beijing Municipality